Compare Dow Jones Industrial Average ETF (DIA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Neurocrine Biosciences Inc — how do they compare? Dow Jones Industrial Average ETF trades at $512.08 (market cap $45.20B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Dow Jones Industrial Average ETF is far larger — about 3.1× Neurocrine Biosciences Inc's market cap, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DIA | NBIX | |
|---|---|---|
Market Cap | $45.20B | $14.36B |
Volume | 4,095,368 | 1,237,180 |
52-Week High | $542.79 | $185.50 |
52-Week Low | $451.37 | $123.10 |
Typical Hold Time | 103 Days | 23 Days |
Sector | — | Health |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $511.02, down 0.68% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF provides exposure to the 30 blue-chip Dow Jones Industrial Average components, offering diversified large-cap value. Recent dividend distributions in 2026 provide income, while broader market sentiment reflects caution amid economic uncertainty and Federal Reserve policy focus.
The outlook for DIA hinges on the performance of the Dow 30 constituents, with potential upside from strong corporate earnings but risks from high bond yields and market volatility. As a passive ETF, its value tracks the index, making macroeconomic trends and interest rate expectations key drivers. Current technical weakness near support at $509 suggests near-term pressure, though long-term investors may find stability in its blue-chip holdings.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
